The Department for Health and Social Care has asked NICE to conduct an appraisal of tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations.
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in mid-May 2021 when we will write to you about how you can get involved.